Investment: Should you invest in ... healthcare?

THE HEALTHCARE sector is a relatively new creation, a varied collection of drug retailers, medical equipment suppliers, private hospitals, nursing homes and companies developing new forms of medical treatment.

The medical services sector is perceived as one of the great growth areas for the millennium, so investors might expect these companies to be showing impressive growth. But healthcare stocks seem to suffer through comparison with their more glamorous cousins in pharmaceuticals and biotech.

The factors affecting all three types of company are broadly similar. Richard Moore of Singer & Friedlander says: "During the second quarter, the US market has led more towards economically sensitive and cyclical stocks. The question we are asking is whether we will see a rotation in the third quarter back into consumer stocks."

Mr Moore believes this is likely, but attention will again focus on companies which make drugs, rather than those which supply them. "The relative rating of cyclical stocks does seem to have peaked in recent weeks, certainly in the US, which tends to led global markets," he says. "And the pharmaceutical sector in the US is trading at a p/e of seven : it has been between five and 50 so it is definitely near the bottom of its range."

David Thornton, UK fund manager for the Witan investment trust, adds: "Pharmaceuticals is a huge sector, with several prominent global players, but the healthcare sector is much smaller and more of a mixed bag. So we would follow only one or two companies in that sector."

Investec Guinness Flight's Alan Beaney says: "The industry background is tough. Those in charge of health budgets are under pressure to cut costs and these guys are relatively easy targets. They are not manufacturing drugs with the security of patent protection and a lot are simply supplying commodity- type products. So there has been a lot of pressure on their pricing, which is why a lot of companies in the sector are coming together to cut costs. The two companies which created of Nycomed Amersham were forced to come together and make a virtue out of a necessity."

Healthcare is usually the least attractive of the three groupings for investors, in activities, and size of the companies. Alan Beaney says: "Healthcare is a small sector in the UK these days. It contains only three major stocks - Nycomed Amersham, Smith & Nephew and SSL International."

David Thornton highlights this last named company, following its creation via a merger of two of the sector's more prominent names. "Seton and Scholl were basically two distributors coming together to rationalise their business. Seton was a drug distributor with good management which added on Scholl's product range."

SSL is also taking over another supplier in a different market. Mr Thornton adds: "SSL is looking to do the same thing with London International, since condoms are distributed through the same outlets. It is the same story of improving distribution, rationalisation and cost cutting, but you have to apply a certain degree of caution about whether there has been sufficient time to bed down the original merger. If you back the management's ability to deliver, then they have a very good opportunity to enhance earnings through the London International acquisition, but it is very much a company specific `special situation'."

Mr Thornton also has a cautious view of Nycomed Amersham. "It has effectively undergone a three-way merger, between the old Amersham International and Nycomed, a Norwegian company, with a Japanese company added in later. It is trying to focus on the areas of nuclear medicine and diagnostic products and it is downplaying its old industrial product range. But it is not an easy company to understand because, when you are putting several companies together, it is difficult to see whether it is working or not."

Anthony Milford, manager of the Framlington Health Fund, says: "Nycomed Amersham has one business that looks particularly interesting, genetic sequencing. But, at the same time, the growth from its prostate cancer treatment has slowed significantly. Some people are also warming to Smith & Nephew. I think it is a better managed company now, but is still not really of interest".

David Thornton says: "Smith & Nephew has been a bit of a sleeper. Its performance has been dull over recent years and a lot its prospects rest on the success of its Dermograph product. Growth has been static, but there is confidence things will pick up. And if you take the view that it is a player in a global growth market with a half-decent franchise, the shares could represent good value, if the management can drive earnings forward." Anthony Milford's unit trust, the highest-profile health sector fund in the UK, hardly holds any companies in the UK healthcare sector. He says: "My major interest is in US biotech companies, where there is a lot more activity and there are many companies making profits. In the UK healthcare sector, you have Nycomed Amersham and Smith & Nephew, both substantial companies, but different in what they do. SSL is a reasonable size, but most other stocks are small, nursing homes, the odd hospital and the like."

Alan Beaney cites the nursing home stocks within the healthcare sector as a prime example of how investments in this area can be blown off course by other forces which are beyond their control. "They have been a little hurt by changes in Government policy. We saw a lot of nursing homes floating a few years ago, but there has been much consolidation. The rules have been tightened up on exactly how much local authorities could spend on nursing homes and, following these `privatisations', you have overcapacity as a result."

Investors will have to look at each stock in the sector on its individual merits. Alan Beaney draws attention to the product of another merger, Alliance Unichem. "We like Alliance Unichem, which is a drug wholesaler and whose chairman is Kenneth Clarke. It came about from a merger between Unichem and Alliance, a French-based pharmaceutical supplier, so they should benefit from growing retail demand in the UK and expansion in Europe."

Alan Beaney points out that the sector remains at the mercy of the purchasers of healthcare services. "The sector is fundamentally suffering from pressure to cut costs, in the UK and the US. It is difficult for health services to cut drugs bills, so they go after the suppliers. In this area, purchasers go to preferred suppliers and seek competitive tendering, so prices tend to get squeezed. Smith & Nephew have had a tough time and they are restructuring."

Richard Moore says: "Pharmaceutical companies have much greater scope to grow their earnings than the healthcare providers, since their driver of growth is the development of new drugs and their release onto the market. Healthcare companies are less involved with that and they are more general service providers."

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksAn introduction to the ground rules of British democracy
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
SPONSORED FEATURES
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Sales Adviser - OTE £24,500

£22500 - £24500 per annum: Recruitment Genius: Inbound and outbound calls with...

Recruitment Genius: Business Development Executive / Sales - OTE £40,000

£18000 - £40000 per annum: Recruitment Genius: This fast growing Insurance Bro...

Guru Careers: Research Associate / Asset Management Research Analyst

£40 - 45k (DOE) + Benefits: Guru Careers: A Research Associate / Research Anal...

The Green Recruitment Company: Graduate Energy Analyst

£20000 Per Annum: The Green Recruitment Company: Summary: The Green Recruitm...

Day In a Page

Turkey's conflict with Kurdish guerrillas in Iraq can benefit Isis in Syria

Turkey's conflict with Kurdish guerrillas in Iraq can benefit Isis in Syria

Turkish President Erdogan could benefit politically from the targeting of the PKK, says Patrick Cockburn
Yvette Cooper: Our choice is years of Tory rule under Jeremy Corbyn or a return to a Labour government

Our choice is years of Tory rule under Corbyn or a return to a Labour government

Yvette Cooper urged Labour members to 'get serious' about the next general election rather than become 'a protest movement'
Singapore's domestic workers routinely exploited and often abused in the service of rich nationals

Singapore's hidden secret of domestic worker abuse

David Cameron was shown the country's shiniest veneer on his tour. What he didn't see was the army of foreign women who are routinely exploited and often abused in the service of rich nationals
Showdown by Shirley Jackson: A previously unpublished short story from the queen of American Gothic

Showdown, by Shirley Jackson

A previously unpublished short story from the queen of American Gothic
10 best DSLRs

Be sharp! 10 best DSLRs

Up your photography game with a versatile, powerful machine
Solved after 200 years: the mysterious deaths of 3,000 soldiers from Napoleon's army

Solved after 200 years

The mysterious deaths of 3,000 soldiers from Napoleon's army
Every regional power has betrayed the Kurds so Turkish bombing is no surprise

Robert Fisk on the Turkey conflict

Every regional power has betrayed the Kurds so Turkish bombing is no surprise
Investigation into wreck of unidentified submarine found off the coast of Sweden

Sunken sub

Investigation underway into wreck of an unidentified submarine found off the coast of Sweden
Instagram and Facebook have 'totally changed' the way people buy clothes

Age of the selfie

Instagram and Facebook have 'totally changed' the way people buy clothes
Not so square: How BBC's Bloomsbury saga is sexing up the period drama

Not so square

How Virginia Woolf saga is sexing up the BBC period drama
Rio Olympics 2016: The seven teenagers still carrying a torch for our Games hopes

Still carrying the torch

The seven teenagers given our Olympic hopes
The West likes to think that 'civilisation' will defeat Isis, but history suggests otherwise

The West likes to think that 'civilisation' will defeat Isis...

...but history suggests otherwise
The bald truth: How one author's thinning hair made him a Wayne Rooney sympathiser

The bald truth

How thinning hair made me a Wayne Rooney sympathiser
Froome wins second Tour de France after triumphant ride into Paris with Team Sky

Tour de France 2015

Froome rides into Paris to win historic second Tour
Fifteen years ago, Concorde crashed, and a dream died. Today, the desire to travel faster than the speed of sound is growing once again

A new beginning for supersonic flight?

Concorde's successors are in the works 15 years on from the Paris crash